(Q51919586)

17 April 2018

title

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. (English)

1 reference

17 April 2018

1 reference

1 reference

Bengt Winblad

1 reference

17 April 2018

Lennart Minthon

1 reference

17 April 2018

Lena Kilander

1 reference

17 April 2018

Sture Eriksson

1 reference

17 April 2018

Stellan Båtsman

1 reference

17 April 2018

Anna-Lena Wetterholm

1 reference

17 April 2018

Catarina Jansson-Blixt

1 reference

17 April 2018

Anders Haglund

1 reference

17 April 2018

Severe Alzheimer's Disease Study Group

1 reference

17 April 2018

language of work or name

English

0 references

publication date

1 April 2006

1 reference

17 April 2018

published in

The Lancet

1 reference

17 April 2018

volume

367

1 reference

17 April 2018

issue

9516

1 reference

17 April 2018

page(s)

1057-1065

1 reference

17 April 2018

Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

1 reference

7 January 2021

Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Severe impairment battery. A neuropsychological test for severely demented patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Cholinergic markers in elderly patients with early signs of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

Cholinesterase inhibitors for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968350-5

7 January 2021

10.1016/S0140-6736(06)68350-5

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018